# ORLADEYO® (berotralstat) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/berotralstat

> The FDA approved ORLADEYO® (berotralstat), sponsored by BIOCRYST PHARMACEUTICALS INC (BCRX), on December 11, 2025 for HAE aged 2 to <12 years.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ORLADEYO® (berotralstat) |
| Codes |  |
| Sponsor | BIOCRYST PHARMACEUTICALS INC (BCRX) https://sec-api.dev/companies/bcrx/catalysts |
| Indications | hae aged 2 to <12 years, [hae aged 2 to 11](https://sec-api.dev/indications/hae-aged-2-to-11), hae aged 2 to <12, hereditary angioedema aged 2 to <12 years, [hereditary angioedema](https://sec-api.dev/indications/hereditary-angioedema), hae aged 2 to 11 years due |
| Modality | small_molecule |
| FDA designations | priority review |

## Timeline

### December 3, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214094 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20201203, review_priority STANDARD; sponsor_name BIOCRYST; product ORLADEYO (BEROTRALSTAT DIHYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214094%22

### 2025: NDA/BLA submission

- Status: scheduled. Date confidence: year.
- First seen 2025-02-24, last confirmed 2025-02-24.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001020): "The company is on track to submit a new drug application (NDA) in 2025 to the U.S. Food and Drug Administration (FDA) to expand the ORLADEYO label to children with HAE aged 2 to 11 using an oral granule formulation." https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/exh_991.htm

### February 24, 2025: interim data readout

- Status: completed, positive. Date confidence: exact. Indication: HAE aged 2 to 11.
- First seen 2025-02-24, last confirmed 2025-02-24.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001020): "Earlier today, the company announced positive results from an interim analysis of the ongoing APeX-P clinical trial evaluating ORLADEYO in children with HAE aged 2 to 11." https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/exh_991.htm

### June 23, 2025: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: HAE aged 2 to 11 years due.
- First seen 2025-08-05, last confirmed 2025-08-05.
- SEC Form 10-Q (accession 0001628280-25-037795): "On June 23, 2025, the FDA extended the PDUFA goal date for our NDA for the use of once-daily ORLADEYO oral granules in pediatric patients with HAE aged 2 to 11 years due to our submission of additional final reports and formulation data, which resulted in a standard three-month extension to the original goal date to provide time for a full review of the submission." https://www.sec.gov/Archives/edgar/data/882796/000162828025037795/bcrx-20250630.htm

### September 12, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-05-14, last confirmed 2025-08-05.
- SEC Form 8-K (accession 0001171843-25-003152): "The FDA also granted priority review of the application, with a Prescription Drug User Fee Act ("PDUFA") target action date of September 12, 2025." https://www.sec.gov/Archives/edgar/data/882796/000117184325003152/f8k_051425.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003152): "-FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025-" https://www.sec.gov/Archives/edgar/data/882796/000117184325003152/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003152): "The FDA also granted Priority Review of the application, with a Prescription Drug User Fee Act (PDUFA) target action date of September 12, 2025." https://www.sec.gov/Archives/edgar/data/882796/000117184325003152/exh_991.htm
- SEC Form 10-Q (accession 0001628280-25-037795): "In addition, we announced that the FDA granted priority review of our NDA, with a Prescription Drug User Fee Act ("PDUFA") target action date of September 12, 2025." https://www.sec.gov/Archives/edgar/data/882796/000162828025037795/bcrx-20250630.htm

### December 11, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: HAE aged 2 to <12 years.
- First seen 2025-12-12, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA219776 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20251211, review_priority PRIORITY; sponsor_name BIOCRYST; product ORLADEYO (BEROTRALSTAT DIHYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219776%22
- SEC Form 8-K (accession 0001171843-25-007909): "On December 12, 2025, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved the Company's new drug application for the use of an oral pellet formulation of once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema aged 2 to <12 years." https://www.sec.gov/Archives/edgar/data/882796/000117184325007909/f8k_121225.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-007909): "RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of an oral pellet formulation of once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years." https://www.sec.gov/Archives/edgar/data/882796/000117184325007909/exh_991.htm
- SEC Form 10-K (accession 0001628280-26-012240): "On December 12, 2025, we announced that the FDA approved our new drug application ("NDA") for the use of an oral pellet formulation of once-daily ORLADEYO for prophylactic therapy in pediatric patients with HAE aged 2 to <12 years." https://www.sec.gov/Archives/edgar/data/882796/000162828026012240/bcrx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-007909): "BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12" https://www.sec.gov/Archives/edgar/data/882796/000117184325007909/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-001119): "In December 2025, the company received FDA approval for the ORLADEYO pellet formulation for patients ages 2 to <12 with HAE, making it the first and only targeted oral prophylactic therapy for children living with HAE." https://www.sec.gov/Archives/edgar/data/882796/000117184326001119/exh_991.htm
- SEC Form 10-K (accession 0001628280-26-012240): "In December 2025, we received FDA approval for the use of an oral pellet formulation of ORLADEYO for prophylactic therapy in pediatric patients with HAE aged 2 to <12 years." https://www.sec.gov/Archives/edgar/data/882796/000162828026012240/bcrx-20251231.htm

### December 12, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: HAE aged 2 to 11.
- First seen 2025-06-25, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-006881): "The Prescription Drug User Fee Act goal date for the company's new drug application for ORLADEYO granules in children with HAE aged 2 to <12 is December 12, 2025." https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-004977): "The Prescription Drug User Fee Act goal date for the company's new drug application for ORLADEYO granules in children with HAE aged 2 to 11 is December 12, 2025." https://www.sec.gov/Archives/edgar/data/882796/000117184325004977/exh_991.htm
- SEC Form 8-K (accession 0001171843-25-004091): "The new PDUFA target action date is December 12, 2025." https://www.sec.gov/Archives/edgar/data/882796/000117184325004091/f8k_062525.htm
- SEC Form 10-Q (accession 0001628280-25-048785): "The Prescription Drug User Fee Act goal date for our new drug application for ORLADEYO granules in children with HAE aged 2 to 11 is December 12, 2025." https://www.sec.gov/Archives/edgar/data/882796/000162828025048785/bcrx-20250930.htm
- openFDA Drugs@FDA: "NDA219776 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20251211, review_priority PRIORITY; sponsor_name BIOCRYST; product ORLADEYO (BEROTRALSTAT DIHYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219776%22

### October 21, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-04, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001628280-26-070112): "On October 21, 2026, we announced that the FDA approved the supplemental new drug application for use of the 150 mg oral pellet formulation of once-daily ORLADEYO for prophylactic therapy in adults and adolescents aged 12 years and older." https://www.sec.gov/Archives/edgar/data/882796/000162828026070112/bcrx-20260930.htm

Calendar months: [June 2025](https://sec-api.dev/fda-calendar/2025-06), [September 2025](https://sec-api.dev/fda-calendar/2025-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/berotralstat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ORLADEYO® (berotralstat) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/berotralstat

```bibtex
@misc{secapidev_pdufa_berotralstat_20261116,
  title        = {ORLADEYO® (berotralstat) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/berotralstat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_berotralstat_20261116","title":"ORLADEYO® (berotralstat) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/berotralstat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
